[Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach].
OBJECTIVE
To determine the expressive level of checkpoint kinase 1 (CHK1) and polo-like kinase 1 (PLK1) and to detect their clinicopathological significance in benign and malignant lesions of the stomach.


METHODS
Envision Tm immunohistochemistry was used to detect the expression level of CHK1 and PLK1 in conventional paraffin-embedded sections from specimens of primary foci (n=59)and metastatic foci of lymph node (n=42) of gastric cancer, peritumoral tissues (n=20), and benign lesions of the stomach (n=95).


RESULTS
The positive rates of CHK1 were significantly higher in gastric cancer than that in different types of benign lesions(P<0.01). The positive rates of PLK1 were significantly higher in gastric cancer than that in peritumoral tissues (P<0.05) and different types of benign lesions (P<0.01), and the positive cases of PLK1 in benign lesion showed atypical hyperplasia. No significant difference of CHK1 and PLK1 expression was found between metastatic foci and corresponding primary foci (P>0.05). The positive rates of CHK1 and PLK1 were significantly lower in the non-metastatic lymph node than that in the metastatic lymph node (P<0.05). The positive rate of CHK1 was significantly lower in histologic grade II than that in the histologic grade III+IV (P<0.05). Positive correlation was found between the expression of CHK1 and PLK1 in gastric cancer tissues (P<0.01).


CONCLUSIONS
The expression level of CHK1 and /or PLK1 might be important biological markers of kinases to reflect the carcinogenesis, progression, biological behaviors, and guide clinical auxiliary treatment of gastric cancer.
Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Hongliang
H
Yao
Zhulin
Z
Yang
Yongguo
Y
Li
D000230:Adenocarcinoma / Q000378:metabolism*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018797:Cell Cycle Proteins / Q000378:metabolism*; D000071877:Checkpoint Kinase 1; D005260:Female; D005756:Gastritis / Q000378:metabolism; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011494:Protein Kinases / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000378:metabolism*; D000097869:Polo-Like Kinase 1
D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D000071877:Checkpoint Kinase 1; D011494:Protein Kinases; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000097869:Polo-Like Kinase 1; C000605867:CHEK1 protein, human